DGAP-News

MagForce AG Installs Fifth NanoActivator(R) in Germany for the Treatment of Brain Tumors at Frankfurt University Hospital

DGAP-News: MagForce AG / Key word(s): Market launch/Miscellaneous
MagForce AG Installs Fifth NanoActivator(R) in Germany for the
Treatment of Brain Tumors at Frankfurt University Hospital

27.04.2015 / 08:30

---------------------------------------------------------------------

MagForce AG Installs Fifth NanoActivator(R) in Germany for the Treatment of
Brain Tumors at Frankfurt University Hospital

Berlin, Germany and Nevada, USA, April 27, 2015 - MagForce AG (Frankfurt,
Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device
company in the field of nanomedicine focused on oncology, today announced
the installation of the fifth NanoActivator(R). The device was installed at
Frankfurt University Hospital to provide NanoTherm(TM) therapy for the
treatment of brain cancers and the clinic will participate in MagForce's
post marketing study. Since NanoTherm(TM) therapy has the European CE mark
(in 27 EU countries), commercial patients can also be treated in Frankfurt.
NanoActivator(R) devices are now available for treatment of patients with
brain tumors at the University Medical Centers in Berlin, Münster, Kiel,
Cologne, and Frankfurt.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(TM) therapy enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. Mithril Capital
Management, a growth-stage technology fund founded by Ajay Royan and Peter
Thiel, along with MagForce AG, are investors and strategic partners in
MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R),
and NanoActivator(R) are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.


Contact:
Anne Hennecke
MC Services AG

T [phone]
F [phone]

Email: [e-mail]



---------------------------------------------------------------------

27.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Regulated Unofficial Market in Berlin, Dusseldorf,
Stuttgart; Open Market (Entry Standard) in Frankfurt


End of News DGAP News-Service
---------------------------------------------------------------------
348669 27.04.2015